FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

C.R.S. 12-280-133 requires any prescription drug outlet outside Colorado that ships, mails or delivers drugs or devices into the state under a prescription order to register with the State Board of Pharmacy. It must disclose its officers and dispensing pharmacists, keep its home-state license active, and submit its most recent home-state inspection report. Board Rule 5.00.15 (3 CCR 719-1) also requires proof of good standing, an inspection report dated within two years from the resident state board or the NABP Verified Pharmacy Program, and a sworn affidavit that the outlet will not ship compounded or other prescription drugs into Colorado without a patient-specific prescription (except as Rule 21.00.20 allows). Under Rule 5.00.70, the outlet must be under the direct charge of a pharmacist manager; the rules reviewed do not say that manager needs a Colorado license.

The statute text comes from an unofficial mirror of the official C.R.S. PDF, current through Fall 2025. 2026 legislative changes were not checked because web search was unavailable. The board's website (dpo.colorado.gov/Pharmacy) blocked automated access, so application-page details were not confirmed.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Board Rule 3.00.20(d) (3 CCR 719-1) says a pharmacist may not dispense a prescription drug to a practitioner on an order that does not list a specific patient, and that 'A prescription order for "office use" is not a valid order.' The only exception in that rule is compounded drugs for veterinarian 'office stock' under C.R.S. 12-280-121. Rule 21.00.20 adds that nonresident prescription drug outlets may not distribute compounded products into Colorado and may ship compounded products only under valid patient-specific prescriptions, again with a limited veterinary exception. C.R.S. 12-280-120(5)(a) lets pharmacies make casual sales only of drugs in the manufacturer's sealed container to practitioners. Office stock of compounded human drugs therefore has to come from an FDA-registered 503B outsourcing facility registered in Colorado.

The veterinary exception (C.R.S. 12-280-121; 12-280-120(6)(b)) is capped at 10% of dosage units dispensed and distributed each year, and nonresident outlets must meet extra inspection conditions to use it. This entry covers human-use office stock only.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

C.R.S. 12-280-133.5 bars a nonresident 503B outsourcing facility from distributing compounded prescription drugs in Colorado without first registering with the Board. The application must include: proof of active FDA 503B registration and a home-state license, permit or registration; officers and the pharmacist in charge; verification of compliance with FDA and home-state requests; and a copy of the most recent FDA inspection report (also Rule 5.00.17). The Board may deny, revoke or suspend the registration if FDA or the home state revokes or does not renew the facility's registration or license. Rule 5.00.00 defines the facility as FDA-registered, outside Colorado, and distributing compounded drugs into the state without a prescription order.

Neither the statute nor the rule requires a Colorado-licensed pharmacist or a separate wholesaler registration for a nonresident 503B. The Board may do a risk-based inspection of a nonresident 503B after a complaint (Rule 5.00.00(e)). Colorado did sign FDA's 2020 standard MOU (MOU 225-21-014, effective 2021-06-29, per FDA's Compounding MOUs page); see the fda_mou topic. The MOU governs 503A interstate distribution, not 503B licensing.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. The Colorado Board of Pharmacy signed MOU 225-21-014, effective June 29, 2021; Colorado is one of only three signatories (with Kentucky and New Hampshire). FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

C.R.S. 18-18-302(1) requires anyone who dispenses controlled substances to hold a 'registration' from the respective licensing board, and defines registration for physicians as the licensing of physicians by the Colorado Medical Board (likewise dentists, podiatrists, optometrists, veterinarians); only manufacturers, distributors, pharmacies and similar entities are separately registered by the Board of Pharmacy. No additional state CS certificate is issued to physicians. NPs and PAs are not named in that definition and practise under their own prescriptive-authority rules plus DEA registration.

Source older than 2 years - possibly stale: the section was last amended effective Aug. 10, 2022 and the printout is the 2024 CRS (uncertified); the 2025 edition was not available at the URL tried. Colorado requires PDMP registration for prescribers (not verified here).

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

C.R.S. 12-280-404(4)(a) requires a practitioner or designee to query the PDMP before prescribing an opioid, except for patients receiving it in a hospital, skilled nursing, residential or correctional facility, cancer pain, palliative or hospice care, post-surgical pain expected to last over 14 days, disasters/mass casualty events, or a single dose for a test or procedure. Subsection (4)(a.5) requires a query before prescribing a benzodiazepine, except for hospice, epilepsy/seizures, spasticity, alcohol withdrawal or neurological conditions. Attempting access during a technical outage counts as compliance. Under 12-30-109(1)(b), repeated failure to comply is grounds for discipline by the prescriber's licensing board.

Source older than 2 years - possibly stale (CRS 2024 official printout; the Public.Law copy labelled current through Fall 2025 shows the same text). Testosterone (C-III) is not caught. The Colorado PDMP page (dpo.colorado.gov/PDMP) gave no scope detail.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

C.R.S. 12-280-120(6)(a) lets a practitioner personally compound and dispense, for any patient under the practitioner's care, any drug the practitioner may prescribe and deems necessary for the condition being treated; the practitioner is exempt from the pharmacy article except the unlawful-acts section (12-280-129). No separate dispensing registration is required under this provision. Controlled substances still need DEA registration.

Statute text read via an unofficial mirror of the Colorado Revised Statutes.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

Since January 1, 2026, a clinician with an out-of-state credential may provide telehealth to patients in Colorado after registering with the applicable regulator; registrants must follow Colorado practice standards (including prescribing rules), may not open an office or see patients in person, and must meet disclosure and emergency-follow-up duties (C.R.S. 12-30-124, amended by SB 25-129). The Colorado Medical Board treats a provider-patient relationship as established whether or not there was an in-person encounter and holds telehealth prescribing to the same standards as in-person care (Policies 40-03 and 40-27). No Colorado telehealth-specific Schedule III limit was found. IMLC: member.

Registration details come from CCHP's quotation of C.R.S. 12-30-124; the SB25-129 page (signed 4/24/2025) confirms the out-of-state telehealth provider requirements but the statute text itself was not read.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

Colorado Medical Board Rule 1.17 defines 'Medical-Aesthetic Services' to include injections of any substance and lets physicians delegate them, as routine technical services not requiring medical judgment, to persons not licensed to perform them. The delegating physician must be trained, insured, personally perform the service in their own practice, be physically in Colorado and able to attend the patient promptly (or name an in-state covering physician), sign a written agreement listing the facility, write procedure and emergency protocols, and supervise through measures such as initial consultations, observation and chart review. Prescribing cannot be delegated, and off-label use needs specific authorization. Delegation to RNs and LPNs is governed by the Nurse Practice Act rather than Rule 1.17. The Colorado Board of Nursing's FAQ adds that Botox injections may be within RN and APN scope as a delegated medical function if the nurse has the knowledge, judgment and ability to perform them safely, but are not within LPN scope.

Rule compilation version 12607; latest effective date shown in the document is 2026-04-30 (recorded as the version date). Rule 1.17 itself was not separately dated in the extract. The Colorado Board of Nursing's policy compilation contains no cosmetic-injection policy.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Colorado Board of Nursing FAQ states that RNs and LPNs are authorized to administer prescription drugs pursuant to an order or prescription issued by a licensed healthcare provider authorized to prescribe in Colorado, and that RNs performing delegated medical functions require supervision. The Board's policy compilation and the Medical Board's policies contain no IV-hydration clinic guidance (checked 2026-09-23). Under Medical Board Rule 1.17, prescribing may not be delegated to unlicensed persons.

FAQ page has no date (accessed 2026-09-23). No Colorado guidance on prior exams, standing orders or mobile IV services was found; answer rests on general rules.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide classifies Colorado as strict, citing the Medical Practice Act (listed as C.R.S. 12-36-117(m), a pre-2019 citation), and MedPath Compliance (reviewed 2026-06-20) lists Colorado as 'Yes (statute)'. MedPath also notes 2025 Colorado laws voiding most provider non-competes (SB25-083) and requiring pre-merger notice for health transactions (SB25-126).

The Colorado statute's exceptions and current section numbers were not fetched; some compilations describe Colorado's doctrine as having significant entity exceptions.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

The Medical Board treats use of Class IIIb or higher lasers or pulsed-light devices as the practice of medicine and lists them among 'Medical-Aesthetic Services' that may be delegated under Rule 1.17 with a written delegation agreement naming the facility, written procedure and emergency protocols, and an in-state delegating physician who is trained, insured and personally performs the service. Class I, II and IIIa devices are not medical services, and the Board's Policy 40-19 says Class I electrolysis devices need no physician oversight. Nurses and PAs perform laser services under their own practice acts and supervision rules. The Board of Nursing FAQ says cosmetic laser use may be within RN scope as a delegated medical function but is not within LPN scope.

Policy 40-19 shows 'Revised 2/22/2024' but also 'Repealed: Effective 11/16/2023' in the compilation — its current status is unclear; Rule 1.17 is the operative rule.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Colorado was not among them, but this research did not confirm its statutes. Colorado's CLIA state agency is Colorado Dept. of Public Health & Environment, Laboratory Services Division (cdphe_cliaprogram@state.co.us, 303-692-3681); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Colorado's rule. Colorado's lab regulator (CLIA state agency) is Colorado Dept. of Public Health & Environment, Laboratory Services Division (cdphe_cliaprogram@state.co.us, 303-692-3681). The question matters for take-home and consumer test kits, not for panels a clinician orders.

A commercial 2026 guide (Just Labs) describes Colorado as low-restriction, with guidelines for genetic testing; not confirmed against state law. The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Colorado is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

HB22-1345 (signed June 3, 2022; C.R.S. §§25-15-601 to -604) phases in PFAS product bans. Cosmetics, indoor textile furnishings and indoor upholstered furniture were added on Jan 1, 2025, after carpets, fabric treatments, food packaging, juvenile products and others in 2024. A 2026 law-firm review notes the statute lists example cosmetics (moisturizers, nail polish, shampoo and others) and excludes prescription products and certain propellants.

Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.